chenodeoxycholic acid has been researched along with Fatty Liver, Nonalcoholic in 113 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 78 (69.03) | 24.3611 |
| 2020's | 35 (30.97) | 2.80 |
| Authors | Studies |
|---|---|
| Angioni, C; Geisslinger, G; Goebel, T; Heering, J; Kahnt, A; Kaiser, A; Merk, D; Paulke, A; Proschak, E; Rotter, M; Schmidt, J; Steinhilber, D; Weiser, T; Weizel, L; Wittmann, S; Wurglics, M | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Ge, X; Guo, S; Jiao, T; Li, C; Liu, Y; Nan, F; Wang, K; Wang, Y; Xie, C; Xie, X; Yin, J; Zhang, C | 1 |
| Anstee, QM; Bonacci, M; Dufour, JF; Goodman, Z; Granston, T; Harrison, SA; Loomba, R; Natha, M; Ratziu, V; Rinella, ME; Sanyal, AJ; Shringarpure, R; Trylesinski, A; Venugopal, A; Younossi, Z | 1 |
| Cai, Z; Deng, L; Geng, X; Hu, L; Jiao, S; Li, Z; Ren, Q; Wang, B; Yang, Y; Zhang, L; Zhou, Z | 1 |
| Abdallah, DM; Allam, RM; Attia, YM; Elmazar, MM; Hammam, OA; Nassar, NN; Tawfiq, RA | 1 |
| Hou, MC; Huang, CC; Huang, SF; Lee, TY; Li, TH; Lin, HC; Liu, SY; Yang, YY | 1 |
| Han, S; Li, B; Li, L; Li, S; Lou, P; Wang, Q; Wang, S; Xia, J; Yuan, Y; Zhuge, A | 1 |
| Chan, KE; Chee, D; Chew, NWS; Fu, CE; Huang, DQ; Muthiah, M; Nah, B; Ng, CH; Noureddin, M; Sanyal, AJ; Siddqui, MS; Tan, C; Tan, DJH; Tang, ASP; Teng, M; Wong, GHZ; Wong, ZY; Xiao, J; Yong, JN; Zeng, RW | 1 |
| DeBosch, BJ | 1 |
| Chen, H; Liu, J; Ma, L; Ma, Y; Sun, J; Yu, J; Yu, X; Zhang, D; Zhang, T; Zhang, Z; Zou, C | 1 |
| Cohen, DE; Freilich, B; Fuchs, M; Hellstern, PA; Kohli, A; Lawitz, EJ; MacConell, L; Owens-Grillo, J; Pockros, PJ; Schiff, E; Shapiro, D; Shringarpure, R; Van Biene, C | 1 |
| Adorini, L; Brescia, P; Galbiati, M; Invernizzi, P; Mileti, E; Mouries, J; Penna, G; Rescigno, M; Silvestri, A; Sorribas, M; Spadoni, I; Wiest, R | 1 |
| Karabouta, Z; Polyzos, SA; Venetsanaki, V | 1 |
| Chalasani, N; Connelly, MA; Dasarathy, S; Guy, C; Loomba, R; Neuschwander-Tetri, BA; Sanyal, AJ; Siddiqui, MS; Tonascia, J; Van Natta, ML; Vuppalanchi, R; Wattacheril, J | 1 |
| Bartneck, M; Levada, K; Omelyanchik, A; Rodionova, V; Weiskirchen, R | 1 |
| Chen, J; Liu, J; Luo, Y; Shi, J; Su, M; Xu, C; Yang, J; Yang, W; Zang, S; Zhao, F; Zheng, M; Zhou, J | 1 |
| Serfaty, L | 1 |
| Abdelmalek, MF; Anstee, QM; Beckebaum, S; Bedossa, P; Boursier, J; Bugianesi, E; Campagna, J; Cortez-Pinto, H; Dufour, JF; Geier, A; Gluud, LL; Goodman, Z; Graupera, I; Harrison, S; Knapple, W; Kowdley, KV; Lawitz, E; Loomba, R; MacConell, L; Mathurin, P; Mazzella, G; Montano-Loza, AJ; Newsome, PN; Olveira, A; Orr, D; Ratziu, V; Rinella, M; Sanyal, AJ; Shapiro, D; Sheikh, MY; Sheridan, D; Shringarpure, R; Trotter, J; Younossi, ZM; Zaru, L | 1 |
| Alvani, R; Eslam, M; Shiha, G | 1 |
| Kountouras, J; Mantzoros, CS; Polyzos, SA | 1 |
| Cui, S; Ge, C; Gonzalez, FJ; Guo, Y; Hao, H; He, Q; Huang, N; Pan, X; Wang, G; Wang, H; Zhang, P; Zhou, J | 1 |
| Badman, MK; Bao, D; Bursulaya, B; Chianelli, D; Chu, A; Groessl, T; Hernandez, ED; Hill, R; Huang, DJ; Joseph, SB; Kim, Y; Laffitte, B; Liu, B; Liu, X; Liu, Y; McNamara, P; Molteni, V; Nelson, J; Phimister, A; Prashad, M; Richmond, W; Roland, J; Rucker, PV; Sancho-Martinez, I; Schlama, T; Schmeits, J; Seidel, HM; Tully, DC; Wu, J; Zoll, J | 1 |
| Behling, C; Chalasani, N; Dasarathy, S; Diehl, AM; Kleiner, D; Kowdley, K; Lavine, J; Loomba, R; Middleton, M; Neuschwander-Tetri, BA; Sanyal, A; Sirlin, C; Terrault, N; Tonascia, J; Van Natta, M | 1 |
| Adorini, L; Anfuso, B; Rosso, N; Tiribelli, C | 1 |
| Bhagani, S; Guaraldi, G; Ingiliz, P; Lemoine, M; Marzolini, C; Maurice, JB; Milic, J; Monteith, K; Morse, CG; Price, JC; Sebastiani, G; Tsochatzis, E | 1 |
| Nakajima, A; Ogawa, Y; Okanoue, T; Sumida, Y; Yoneda, M | 1 |
| Kowdley, KV; Shah, RA | 1 |
| Chapman, RW; Lynch, KD | 1 |
| Attia, SL; Mouzaki, M; Softic, S | 1 |
| Attema, J; Caspers, MPM; de Ruiter, C; Kleemann, R; Menke, AL; Radhakrishnan, S; Salic, K; van den Hoek, AM; van Nieuwkoop, A; Verschuren, L; Worms, N | 1 |
| Gao, L; Guo, S; Li, J; Li, Y; Liu, H; Liu, M; Ru, H; Shu, Z; Sun, DD; Tan, Q; Xie, R; Zang, Y; Zhou, Y | 1 |
| Bawa, FC; Chen, S; Gopoju, R; Hu, S; Pan, X; Stroup, D; Xu, Y; Yin, L; Zhang, Y; Zhu, Y | 1 |
| Abdelmalek, MF | 1 |
| Geier, A; Rau, M | 1 |
| Ali, AA; Attia, YM; Elmazar, MM; Gibriel, AA; Hammam, OA; Kassem, DH; Tawfiq, RA | 1 |
| Arab, JP; Candia, R; Kulkarni, AV; Kumar, P; Padaki, NR; Premkumar, M; Reddy, DN; Sharma, M; Tevethia, HV | 1 |
| Chen, Y; Li, T; Lu, Z; Ye, F; Yu, J; Zhang, X; Zhou, J | 1 |
| Dou, B; Fan, S; Huang, C; Huang, J; Huang, L; Li, J; Liu, C; Zheng, P; Zhou, Z | 1 |
| Baldoni, M; Biagioli, M; Distrutti, E; Fiorucci, S; Ricci, P; Sepe, V; Zampella, A | 1 |
| Bai, F; Huang, S; Leng, Y; Qin, L; Sun, K; Tang, W; Wang, H; Wu, B; Wu, Y; Zhao, Z | 1 |
| Kremoser, C | 1 |
| Chen, J; Gu, X; Luo, H; Su, C; Tang, J; Xiao, L; Xiong, F; Zha, L; Zhao, Y; Zheng, Z | 1 |
| Anstee, QM; Barritt, AS; Bonacci, M; Cawkwell, G; Harrison, S; Loomba, R; Nader, F; Noureddin, M; Ratziu, V; Rinella, M; Sanyal, AJ; Schattenberg, JM; Stepanova, M; Wong, B; Younossi, ZM | 1 |
| Eguchi, A; Hara, N; Hasegawa, H; Iwasa, M; Iwata, K; Kobayashi, Y; Mifuji-Moroka, R; Sugimoto, R; Taguchi, O; Takei, Y; Tanaka, H | 1 |
| Afonso, MB; Borralho, PM; Carvalho, CC; Castro, RE; Cortez-Pinto, H; Duarte, A; Machado, MV; Rodrigues, CM; Rodrigues, PM; Simão, AL; Trindade, A | 1 |
| Bashir, MR; Brunt, EM; Doo, E; Fowler, KJ; Heba, ER; Hooker, CA; Kleiner, DE; Lavine, JE; Loomba, R; Middleton, MS; Neuschwander-Tetri, BA; Sandrasegaran, K; Sanyal, A; Sirlin, CB; Van Natta, ML | 1 |
| Kim, W | 1 |
| Chan, HL; Chan, WK; Chawla, Y; Chitturi, S; Dan, YY; Duseja, A; Fan, J; Farrell, G; Goh, KL; Hamaguchi, M; Hashimoto, E; Kim, SU; Lesmana, LA; Lin, YC; Liu, CJ; Ni, YH; Sollano, J; Wong, GL; Wong, SK; Wong, VW | 1 |
| Aguilera, V; Ampuero, J; Bellido, F; Romero-Gómez, M; Sánchez-Torrijos, Y | 1 |
| Claudel, T; Fuchs, CD; Scharnagl, H; Stojakovic, T; Trauner, M | 1 |
| Bush, H; Golabi, P; Younossi, ZM | 1 |
| Andreone, P; Gitto, S; Guarneri, V; Sartini, A | 1 |
| Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L | 1 |
| Chalasani, N; Gawrieh, S | 1 |
| Briand, F; Brousseau, E; Burcelin, R; Quinsat, M; Sulpice, T | 1 |
| Drew, L | 1 |
| Chalasani, N; Gill, RM; Hameed, B; Hoofnagle, JH; Loomba, R; Terrault, NA; Van Natta, ML | 1 |
| Feigh, M; Gillum, MP; Hansen, HH; Jelsing, J; Kristiansen, MN; Rigbolt, KT; Tølbøl, KS; Veidal, SS; Vrang, N | 1 |
| Browning, MG; Campos, GM; Khoraki, J; Mazzini, GS | 1 |
| Eslam, M; George, J | 1 |
| Hofmann, AF; Marschall, HU | 1 |
| Cremonesi, A; Gai, Z; Gui, T; Hartling, I; Häusler, S; Hiller, C; Kullak-Ublick, GA; Thasler, WE; Visentin, M; Zhao, L | 1 |
| Asakawa, M; Goto, T; Itoh, M; Kai, T; Kanai, S; Ogawa, Y; Sakai, T; Shirakawa, I; Suganami, T; Yoneyama, T | 1 |
| Grønbæk, H; Heebøll, S; Vilstrup, H | 1 |
| Kumar, RB; Mathews, SE; Shukla, AP | 1 |
| Abdelmalek, MF; Chalasani, NP; Chen, J; Ferguson, B; Kowdley, KV; Lee, L; Liberman, A; Loomba, R; McCullough, AJ; Neuschwander-Tetri, BA; Sanyal, AJ; Shapiro, D; Shringarpure, R; Terrault, N | 1 |
| Abdelmalek, MF; Chalasani, N; Dasarathy, S; Ferguson, B; Kowdley, KV; Loomba, R; McCullough, AJ; Neuschwander-Tetri, BA; Sanyal, AJ; Shapiro, D; Shringarpure, R; Terrault, N | 1 |
| Khorasanizadeh, S; Kirby, RJ; Malany, S; Parafati, M; Rastinejad, F | 1 |
| Broermann, A; Feigh, M; Gillum, MP; Hansen, HH; Jelsing, J; Rigbolt, KTG; Rippmann, JF; Schönberger, T; Stierstorfer, B; Tølbøl, KS; Veidal, SS; Vrang, N | 1 |
| Brunt, EM; Kleiner, DE; Neuschwander-Tetri, BA; Sanyal, AJ; Wilson, LA | 1 |
| Shetty, A; Syn, WK | 1 |
| Rockey, DC | 1 |
| Hye Khan, MA; Imig, JD; Merk, D; Schmidt, J; Stavniichuk, A | 1 |
| Gege, C; Hambruch, E; Hambruch, N; Kinzel, O; Kremoser, C | 1 |
| Al-Hamoudi, WK; Al-Judaibi, B; Al-Osaimi, A; Alswat, KA; Alturaify, N; Elsiesy, HA; Fallatah, HI; Qutub, AN | 1 |
| Anstee, QM; Bedossa, P; Goodman, Z; Harrison, S; Loomba, R; MacConell, L; Ratziu, V; Rinella, M; Sanyal, AJ; Shah, A; Shringarpure, R; Younossi, Z | 1 |
| Biagioli, M; Carino, A; Distrutti, E; Fiorucci, C; Fiorucci, S; Marchianò, S; Monti, MC; Ricci, P; Scarpelli, P; Zampella, A | 1 |
| Alukal, JJ; Thuluvath, PJ | 1 |
| Adorini, L; Castelloe, E; Clopton, P; Dillon, P; Henry, RR; Kipnes, M; Marschall, HU; Morrow, L; Mudaliar, S; Pruzanski, M; Sanyal, AJ; Sciacca, CI; Shapiro, D | 1 |
| Karpen, SJ | 1 |
| Hayashi, Y; Ishii, A; Jia, X; Kaneko, R; Kato, M; Kitamori, K; Naito, H; Nakajima, T; Nomura, M; Suzuki, Y; Yamori, Y; Yetti, H; Zaitsu, K | 1 |
| Adorini, L; Cellai, I; Comeglio, P; Filippi, S; Galli, A; Maggi, M; Maneschi, E; Mannucci, E; Morelli, A; Rastrelli, G; Saad, F; Sarchielli, E; Vannelli, GB; Vignozzi, L | 1 |
| Anavi, S; Hahn-Obercyger, M; Tirosh, O; Voloshin, I | 1 |
| Cortez-Pinto, H; Machado, MV | 1 |
| Ray, K | 1 |
| Ratziu, V | 1 |
| Abdelmalek, MF; Brunt, EM; Chalasani, N; Clark, JM; Dasarathy, S; Diehl, AM; Doo, E; Hameed, B; Kleiner, DE; Kowdley, KV; Lavine, JE; Loomba, R; McCullough, A; Neuschwander-Tetri, BA; Sanyal, AJ; Terrault, N; Tonascia, J; Van Natta, ML | 1 |
| Rinella, ME; Sanyal, AJ | 1 |
| Carr, RM; Reid, AE | 1 |
| Chan, FK; Wong, GL; Wong, VW | 1 |
| Musso, G | 1 |
| Pariente, A | 1 |
| Sanyal, AJ | 1 |
| Chi, KR | 1 |
| Cassader, M; Gambino, R; Musso, G | 1 |
| Armstrong, MJ; Newsome, PN | 1 |
| Brunt, EM; Kleiner, DE; Neuschwander-Tetri, BA; Tonascia, J; Van Natta, ML | 1 |
| Allen, AM; Khera, R; Loomba, R; Murad, MH; Singh, S | 1 |
| Gai, Z; Gui, T; Hiller, C; Kullak-Ublick, GA | 1 |
| Berends, FJ; Betzel, B; Hollman, DAA; Ijssennagger, N; Janssen, AWF; Janssen, IM; Kersten, S; Milona, A; Mokry, M; Ramos Pittol, JM; van Mil, SWC | 1 |
| Hameed, B; Terrault, N | 1 |
| Chaiyakunapruk, N; Chongmelaxme, B; Kowdley, KV; Phisalprapa, P; Saokaew, S; Sawangjit, R; Thakkinstian, A | 1 |
| Mintziori, G; Polyzos, SA | 1 |
| Rotman, Y; Sanyal, AJ | 1 |
| Dufour, JF; Perazzo, H | 1 |
| Jun, DW; Nguyen, MH; Oh, H; Saeed, WK | 1 |
| Alawad, AS; Levy, C | 1 |
| Duan, XP; Huo, XK; Liu, KX; Liu, ZH; Meng, Q; Peng, JY; Sun, HJ; Sun, PY; Wang, CY | 1 |
| Cholongitas, E; Makri, E; Tziomalos, K | 1 |
| Blackman, BR; Cole, BK; Collado, MS; Dash, A; Feaver, RE; Figler, RA; Hoang, SA; Lawson, MJ; Mackey, AJ; Manka, D; Marukian, S; Sanyal, AJ; Wamhoff, BR | 1 |
| Costa, SM; Couto, CA; Lisboa, QC | 1 |
| Adorini, L; Pruzanski, M; Shapiro, D | 1 |
39 review(s) available for chenodeoxycholic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals.
Topics: Chenodeoxycholic Acid; Humans; Longitudinal Studies; Non-alcoholic Fatty Liver Disease; Pruritus | 2023 |
Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
Topics: Animals; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2019 |
Magnetic-Assisted Treatment of Liver Fibrosis.
Topics: Animals; Benzamides; Benzothiazoles; Chenodeoxycholic Acid; Hepatic Stellate Cells; Humans; Imidazoles; Liver Cirrhosis; Macrophages; Magnetic Fields; Nanomedicine; Non-alcoholic Fatty Liver Disease; Pyridines; Sulfonamides | 2019 |
[Pharmacological treatment of NASH].
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Cytoprotection; Glucagon-Like Peptide 1; Humans; Imidazoles; Insulin Resistance; Metformin; Non-alcoholic Fatty Liver Disease; Patient Selection; Pharmaceutical Preparations; Propionates; Sulfoxides; Thiazolidinediones | 2019 |
Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
Topics: Animals; Chenodeoxycholic Acid; Clinical Trials as Topic; Humans; Non-alcoholic Fatty Liver Disease | 2020 |
Current and new pharmacotherapy options for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Vitamin E | 2020 |
Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chenodeoxycholic Acid; Clinical Trials as Topic; Disease Progression; Gastrointestinal Agents; Healthy Lifestyle; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2020 |
Obeticholic acid-a new therapy in PBC and NASH.
Topics: Chenodeoxycholic Acid; Gastrointestinal Agents; Humans; Liver Cirrhosis, Biliary; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2020 |
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibroblast Growth Factors; Glucosides; Humans; Imidazoles; Isobutyrates; Liraglutide; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oxazoles; Polyethylene Glycols; Pyridazines; Pyrimidines; Severity of Illness Index; Sulfoxides; Treatment Outcome; Uracil | 2021 |
Nonalcoholic fatty liver disease: another leap forward.
Topics: Chenodeoxycholic Acid; Disease Progression; Gastrointestinal Agents; Humans; Imaging, Three-Dimensional; Liver; Machine Learning; Non-alcoholic Fatty Liver Disease | 2021 |
An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.
Topics: Anti-Inflammatory Agents; Chenodeoxycholic Acid; Drug Development; Humans; Non-alcoholic Fatty Liver Disease; Prevalence | 2021 |
Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Topics: Chenodeoxycholic Acid; Cholestasis; Humans; Liver Cirrhosis, Biliary; Non-alcoholic Fatty Liver Disease; Pharmaceutical Preparations; Ursodeoxycholic Acid | 2021 |
The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chalcones; Chenodeoxycholic Acid; Cholesterol, HDL; Cholesterol, LDL; Curcumin; Enzyme Inhibitors; Humans; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Plant Preparations; Propionates; Triglycerides | 2021 |
[Treatment Options in Non-alcoholic Fatty Liver Disease].
Topics: Antibodies, Monoclonal, Humanized; Chalcones; Chenodeoxycholic Acid; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Propionates; Receptors, Cytoplasmic and Nuclear; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups.
Topics: Adolescent; Asia; Bariatric Surgery; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Child; Diet; Exercise; Fatty Acids, Omega-3; Gastroenterology; Humans; Liver Neoplasms; Liver Transplantation; Non-alcoholic Fatty Liver Disease; Obesity; Pacific Islands; Practice Guidelines as Topic; Risk; Systematic Reviews as Topic; Thiazolidinediones; Vitamin E | 2018 |
New therapeutic perspectives in non-alcoholic steatohepatitis.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Clinical Trials as Topic; Combined Modality Therapy; Diet, Mediterranean; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Dyslipidemias; Endoscopy; Exercise Therapy; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Humans; Insulin Resistance; MAP Kinase Kinase Kinase 5; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Weight Loss | 2018 |
Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Topics: Antioxidants; Chenodeoxycholic Acid; Cholic Acids; Diet Therapy; Exercise; Free Radical Scavengers; Humans; Hypoglycemic Agents; Life Style; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Vitamin E | 2017 |
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
Topics: Animals; Chenodeoxycholic Acid; Cholangitis, Sclerosing; Disease Models, Animal; Humans; Hypertension, Portal; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome | 2018 |
Nonalcoholic fatty liver disease: Evolving paradigms.
Topics: Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Diagnostic Imaging; Diet, Reducing; Dyslipidemias; Exercise Therapy; Humans; Hyperuricemia; Hypoglycemic Agents; Liver; Liver Function Tests; Liver Neoplasms; Mass Screening; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Assessment; Risk Factors; Vitamin E | 2017 |
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Topics: Antibodies, Monoclonal, Humanized; CCR5 Receptor Antagonists; Chalcones; Chenodeoxycholic Acid; Clinical Trials, Phase II as Topic; Cysteamine; Cystine Depleting Agents; Humans; Imidazoles; Incretins; Liraglutide; Non-alcoholic Fatty Liver Disease; Propionates; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sulfoxides | 2018 |
[Treatment of non-alcoholic fatty liver disease].
Topics: Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Critical Pathways; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Risk Assessment; Vitamin E | 2018 |
Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet; Exercise; Heart Diseases; Humans; Life Style; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Vitamin E | 2018 |
Current treatment options for nonalcoholic fatty liver disease.
Topics: Antioxidants; Bariatric Surgery; Chalcones; Chenodeoxycholic Acid; Coffee; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Receptors, Cytoplasmic and Nuclear; Sleep; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E | 2019 |
Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
Topics: Chenodeoxycholic Acid; Humans; Ligands; Liver Diseases; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2019 |
Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Chalcones; Chenodeoxycholic Acid; Diagnostic Imaging; Healthy Lifestyle; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Liver; Liver Transplantation; Mass Screening; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prevalence; Propionates; Thiazolidinediones; Vitamin E | 2019 |
Reversal of NASH fibrosis with pharmacotherapy.
Topics: Benzamides; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Imidazoles; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Propionates; Pyridines; Risk Factors; Sulfoxides | 2019 |
NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.
Topics: Anticholesteremic Agents; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Membrane Proteins; Non-alcoholic Fatty Liver Disease | 2015 |
FXR agonists as therapeutic agents for non-alcoholic fatty liver disease.
Topics: Bile Acids and Salts; Chenodeoxycholic Acid; Cholagogues and Choleretics; Fatty Liver, Alcoholic; Humans; NF-kappa B; Non-alcoholic Fatty Liver Disease; Phosphoenolpyruvate Carboxykinase (ATP); PPAR alpha; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Ursodeoxycholic Acid | 2015 |
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Humans; Insulin Resistance; Lipid Metabolism; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2015 |
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Topics: Chenodeoxycholic Acid; Drug Therapy, Combination; Humans; Non-alcoholic Fatty Liver Disease; Pioglitazone; Publication Bias; Rosiglitazone; Thiazolidinediones; Vitamin E | 2015 |
Emerging Therapies for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antioxidants; Caspase Inhibitors; Chenodeoxycholic Acid; Cholic Acids; Fatty Acids, Omega-3; Humans; Incretins; Insulin Resistance; Liraglutide; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Pectins; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.
Topics: Antioxidants; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Pentoxifylline; Thiazolidinediones; Treatment Outcome; Vitamin E | 2016 |
Emerging and future therapies for nonalcoholic steatohepatitis in adults.
Topics: Adult; Chenodeoxycholic Acid; Drug Design; Glucagon-Like Peptide 1; Humans; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Thiazolidinediones; Vitamin E | 2016 |
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
Topics: Anti-Obesity Agents; Antioxidants; Chenodeoxycholic Acid; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Drug Repositioning; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Incretins; Lipogenesis; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Tumor Necrosis Factor-alpha | 2017 |
The therapeutic landscape of non-alcoholic steatohepatitis.
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss | 2017 |
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
Topics: Biomarkers; Chenodeoxycholic Acid; Clinical Trials as Topic; Fatty Liver; Fibrosis; Humans; Liver; Magnetic Resonance Imaging; Non-alcoholic Fatty Liver Disease; Tomography, X-Ray Computed; Ultrasonography; Vitamin E | 2016 |
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2016 |
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
Topics: Animals; Chenodeoxycholic Acid; Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2012 |
12 trial(s) available for chenodeoxycholic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Topics: Adult; Aged; Atorvastatin; Bile Acids and Salts; Chenodeoxycholic Acid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; United States | 2019 |
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Topics: Adult; Biopsy; Chenodeoxycholic Acid; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2020 |
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Topics: Administration, Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease | 2019 |
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Topics: Adipose Tissue; Adult; Aged; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Protons; Weight Loss | 2020 |
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis.
Topics: Adult; Aged; Chenodeoxycholic Acid; Double-Blind Method; Female; Fibrosis; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pruritus; Quality of Life | 2022 |
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
Topics: Adiposity; Adult; Area Under Curve; Biopsy; Chenodeoxycholic Acid; Female; Humans; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; ROC Curve; Single-Blind Method | 2017 |
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
Topics: Adult; Alkaline Phosphatase; Biopsy; Body Weight; Chenodeoxycholic Acid; Cholesterol, LDL; Double-Blind Method; Female; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Weight Loss | 2018 |
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Topics: Adult; Biomarkers; Biopsy; Chenodeoxycholic Acid; Clinical Enzyme Tests; Decision Support Techniques; Female; Gastrointestinal Agents; Humans; Ligands; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Predictive Value of Tests; Receptors, Cytoplasmic and Nuclear; Time Factors; Treatment Outcome; United States | 2019 |
Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
Topics: Adult; Biomarkers; Biopsy; Chenodeoxycholic Acid; Female; Humans; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; United States | 2019 |
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Dose-Response Relationship, Drug; Health Resources; Health Services; Humans; Liver Cirrhosis; Liver Transplantation; Longitudinal Studies; Non-alcoholic Fatty Liver Disease | 2019 |
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Topics: Adult; Aged; Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2013 |
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Topics: Administration, Oral; Chenodeoxycholic Acid; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Weight Loss | 2015 |
62 other study(ies) available for chenodeoxycholic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents; Drug Discovery; Enzyme Inhibitors; Epoxide Hydrolases; HeLa Cells; Hep G2 Cells; Humans; Liver; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship | 2017 |
Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis.
Topics: Animals; Betulinic Acid; Bile Acids and Salts; Ceramides; Fibrosis; Glucose; Inflammasomes; Inflammation; Islet Amyloid Polypeptide; Liver; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pentacyclic Triterpenes; Receptors, Cytoplasmic and Nuclear | 2022 |
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Topics: Adult; Aged; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Placebos | 2022 |
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
Topics: Animals; Chenodeoxycholic Acid; Drug Discovery; Gene Expression Regulation; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Models, Molecular; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Protein Binding; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2022 |
Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis.
Topics: Animals; Autophagy; Chenodeoxycholic Acid; Ileum; Mice; Non-alcoholic Fatty Liver Disease; Tight Junctions; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2022 |
Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
Topics: Animals; Chenodeoxycholic Acid; Fibrosis; Heart Diseases; Interleukin-10; Mice; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2022 |
Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice.
Topics: Animals; Chenodeoxycholic Acid; Lipid Peroxidation; Liver; Mice; Microbiota; Non-alcoholic Fatty Liver Disease | 2023 |
Next-Generation Farnesoid X Receptor Agonists in NASH Treatment: Are We There Yet?
Topics: Bile Acids and Salts; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease | 2023 |
Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Gastrointestinal Microbiome; Mice; Non-alcoholic Fatty Liver Disease | 2023 |
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Topics: Animals; Bacterial Translocation; Capillary Permeability; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Insulin Resistance; Intestinal Mucosa; Liver; Mice; Non-alcoholic Fatty Liver Disease; Protective Agents | 2019 |
Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis.
Topics: Adult; Bile Acids and Salts; Chenodeoxycholic Acid; Cholic Acids; Cohort Studies; Disease Progression; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors | 2019 |
Obeticholic acid: towards first approval for NASH.
Topics: Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease | 2019 |
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
Topics: Animals; Cells, Cultured; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Hepatic Stellate Cells; Humans; Lipid Droplets; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Perilipin-1; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Sumoylation; Transcriptional Activation; Treatment Outcome | 2020 |
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis.
Topics: Animals; Benzothiazoles; Chenodeoxycholic Acid; Diet, High-Fat; Dogs; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protein Structure, Tertiary; Rats; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2020 |
Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.
Topics: Benzamides; Benzothiazoles; Bile Acids and Salts; Cell Line; Chenodeoxycholic Acid; Coculture Techniques; Collagen; Fatty Acids, Nonesterified; Hepatic Stellate Cells; Hepatocytes; Humans; Imidazoles; Isoxazoles; Liver; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Non-alcoholic Fatty Liver Disease; Protein Kinase Inhibitors; Pyridines; Receptors, Cytoplasmic and Nuclear; RNA-Binding Proteins | 2020 |
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
Topics: Anti-Retroviral Agents; Chalcones; Chenodeoxycholic Acid; Cholic Acids; Clinical Trials, Phase III as Topic; Drug Interactions; HIV Infections; Humans; Imidazoles; Non-alcoholic Fatty Liver Disease; Propionates; Pyridazines; Sulfoxides; Uracil | 2020 |
A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Fast Foods; Hyperinsulinism; Hyperlipidemias; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, LDL; Transcriptome; Treatment Outcome | 2020 |
Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
Topics: Animals; Binding Sites; Chemical and Drug Induced Liver Injury; Chenodeoxycholic Acid; Drug Design; Drug Evaluation, Preclinical; Half-Life; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship | 2020 |
Hepatocyte Nuclear Factor 4α Prevents the Steatosis-to-NASH Progression by Regulating p53 and Bile Acid Signaling (in mice).
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol 7-alpha-Hydroxylase; Diet, High-Fat; Hepatocyte Nuclear Factor 4; Hepatocytes; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction; Steroid 12-alpha-Hydroxylase; Triglycerides; Tumor Suppressor Protein p53 | 2021 |
Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Topics: Animals; Carcinoma, Hepatocellular; Chenodeoxycholic Acid; Janus Kinase 2; Liver Neoplasms; Male; Mice; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein | 2021 |
Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
Topics: Animals; Carbon Tetrachloride; Chenodeoxycholic Acid; Diet; Inflammation; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phenyl Ethers | 2021 |
The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.
Topics: Azetidines; Chenodeoxycholic Acid; Humans; Isonicotinic Acids; Liver; Non-alcoholic Fatty Liver Disease | 2021 |
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Topics: Animals; Cells, Cultured; Chenodeoxycholic Acid; Down-Regulation; Inflammasomes; Kupffer Cells; Macrophages; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease | 2021 |
FXR agonists for NASH: How are they different and what difference do they make?
Topics: Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2021 |
Soyasaponin A
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Choline Deficiency; Colon; Diet; Disease Models, Animal; Gastrointestinal Microbiome; Inflammation; Liver; Male; Methionine; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Saponins | 2021 |
The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD).
Topics: Bile Acids and Salts; Chenodeoxycholic Acid; Deoxycholic Acid; Energy Metabolism; Female; Glucose; Humans; Lipid Metabolism; Liver; Male; Middle Aged; Muscle, Skeletal; Non-alcoholic Fatty Liver Disease; Receptors, G-Protein-Coupled; RNA-Binding Proteins | 2017 |
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
Topics: Animals; Apoptosis; Chenodeoxycholic Acid; Disease Models, Animal; Fast Foods; Inflammation; Liver Cirrhosis; Male; Mice; Mice, Knockout; MicroRNAs; Non-alcoholic Fatty Liver Disease; PPAR alpha; Receptors, Cytoplasmic and Nuclear | 2017 |
FXR controls CHOP expression in steatohepatitis.
Topics: Animals; Binding Sites; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Glucose; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Promoter Regions, Genetic; Protein Binding; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; RNA, Messenger; Signal Transduction; Transcription Factor CHOP; Tretinoin | 2017 |
Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Topics: Animals; Body Weight; CD36 Antigens; Chenodeoxycholic Acid; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Diet; Disease Models, Animal; Dyslipidemias; Gene Expression Regulation; Insulin Resistance; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Receptors, LDL | 2018 |
Drug development: Sprint finish.
Topics: Animals; Biotechnology; Cardiovascular Diseases; Chenodeoxycholic Acid; Clinical Trials as Topic; Drug Discovery; Drug Industry; Hepatitis C; Humans; Liver Cirrhosis; Mice; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease | 2017 |
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Topics: Animals; Biopsy; Chalcones; Chenodeoxycholic Acid; Collagen Type I; Collagen Type I, alpha 1 Chain; Diet, High-Fat; Disease Models, Animal; Galectin 3; Lipid Metabolism; Liraglutide; Liver; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Propionates; Time Factors; Weight Gain | 2018 |
Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.
Topics: Animals; Chenodeoxycholic Acid; Liver; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease | 2018 |
Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH.
Topics: Chenodeoxycholic Acid; Humans; Liver; Non-alcoholic Fatty Liver Disease | 2018 |
Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form.
Topics: Bile; Bile Acids and Salts; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease | 2018 |
Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
Topics: Animals; Arachidonic Acid; Cell Movement; Cells, Cultured; Chenodeoxycholic Acid; Cytochrome P-450 Enzyme System; Diet, High-Fat; Disease Models, Animal; Female; Gene Expression Regulation; Hepatocytes; Humans; Lipid Metabolism; Mice; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Signal Transduction; THP-1 Cells | 2018 |
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Topics: Animals; Body Weight; Cell Death; Chenodeoxycholic Acid; Cytoprotection; Disease Models, Animal; Disease Progression; Gene Knockout Techniques; Hepatocytes; Insulin Resistance; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Receptor, Melanocortin, Type 4; Tumor Suppressor Protein p53 | 2018 |
A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis.
Topics: Cell Shape; Cells, Cultured; Chenodeoxycholic Acid; Endoplasmic Reticulum Stress; Fatty Acids; Gene Expression Regulation; Gene Ontology; Hepatocytes; Humans; Induced Pluripotent Stem Cells; Lipogenesis; Models, Biological; Non-alcoholic Fatty Liver Disease; Phenotype; Receptors, Cytoplasmic and Nuclear; Thapsigargin; Time Factors; Transcriptome; Triglycerides; Unfolded Protein Response; Up-Regulation | 2018 |
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
Topics: Animals; Chalcones; Chenodeoxycholic Acid; Cholesterol; Disease Progression; Male; Non-alcoholic Fatty Liver Disease; Nutrients; Propionates; Rats; Rats, Wistar | 2019 |
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Retrospective Studies; Treatment Outcome; Vitamin E; Vitamins | 2019 |
Editorial: Advances in Hepatology: 2019.
Topics: Antiviral Agents; Blood Coagulation Disorders; Chemical and Drug Induced Liver Injury; Chenodeoxycholic Acid; End Stage Liver Disease; Gastroenterology; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Liver Diseases; Non-alcoholic Fatty Liver Disease; Palliative Care | 2019 |
A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
Topics: Animals; Chenodeoxycholic Acid; Diet, High-Fat; Dose-Response Relationship, Drug; Epoxide Hydrolases; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2019 |
Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Topics: Animals; Chenodeoxycholic Acid; Diet; Dysbiosis; Humans; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Signal Transduction; Ursodeoxycholic Acid | 2019 |
Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD?
Topics: Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2013 |
A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model.
Topics: Animals; Biomarkers; Chenodeoxycholic Acid; Cholic Acid; Chromatography, Liquid; Deoxycholic Acid; Diet, High-Fat; Fatty Liver; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Random Allocation; Rats; Tandem Mass Spectrometry | 2014 |
Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
Topics: Acetylcholine; Animals; Antibodies, Monoclonal; Chenodeoxycholic Acid; Diet, High-Fat; Dietary Fats; Erectile Dysfunction; Fatty Liver; Gene Expression; Humans; Imidazoles; Infliximab; Liver; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Rabbits; Receptors, Cytoplasmic and Nuclear; Sulfones; Testosterone; Triazines; Tumor Necrosis Factor-alpha; Vardenafil Dihydrochloride | 2014 |
L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease.
Topics: Animals; Arginine; Body Weight; Chenodeoxycholic Acid; Eating; Esters; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2014 |
Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?
Topics: Bile Acids and Salts; Chenodeoxycholic Acid; Energy Metabolism; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, Cytoplasmic and Nuclear | 2014 |
NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
Topics: Chenodeoxycholic Acid; Gastrointestinal Agents; Humans; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2015 |
Starting the battle to control non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Female; Humans; Male; Non-alcoholic Fatty Liver Disease | 2015 |
Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
Topics: Chenodeoxycholic Acid; Female; Humans; Male; Non-alcoholic Fatty Liver Disease | 2015 |
Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chenodeoxycholic Acid; Humans; Non-alcoholic Fatty Liver Disease; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Resveratrol; Stilbenes | 2015 |
[Not Available].
Topics: Chenodeoxycholic Acid; Female; Humans; Male; Non-alcoholic Fatty Liver Disease | 2015 |
The NASH drug dash.
Topics: Animals; Anticholesteremic Agents; Chenodeoxycholic Acid; Clinical Trials as Topic; Drug Industry; Humans; Non-alcoholic Fatty Liver Disease | 2015 |
Trials of obeticholic acid for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Female; Humans; Male; Non-alcoholic Fatty Liver Disease | 2015 |
Trials of obeticholic acid for non-alcoholic steatohepatitis.
Topics: Chenodeoxycholic Acid; Female; Humans; Male; Non-alcoholic Fatty Liver Disease | 2015 |
Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.
Topics: Chenodeoxycholic Acid; Female; Humans; Male; Non-alcoholic Fatty Liver Disease | 2015 |
Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
Topics: Aldehydes; Animals; Bile Acids and Salts; CCAAT-Enhancer-Binding Proteins; Chenodeoxycholic Acid; Diet, High-Fat; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fatty Acids, Nonesterified; Female; Glutathione; Heat-Shock Proteins; Humans; Kidney; Kidney Diseases; Kidney Tubules; Lipid Metabolism; Lipid Peroxidation; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Middle Aged; Nephrectomy; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear | 2016 |
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; DNA; Gene Expression Profiling; Gene Expression Regulation; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Microarray Analysis; Non-alcoholic Fatty Liver Disease; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Transcriptional Activation | 2016 |
Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
Topics: Animals; Chenodeoxycholic Acid; Cholestenones; Choline Deficiency; Dose-Response Relationship, Drug; Fibrosis; Gene Expression; Hepatocytes; Lipid Metabolism; Lipogenesis; Liver; Male; Methionine; Mice; Non-alcoholic Fatty Liver Disease; Pregnenediones; Primary Cell Culture; Protective Agents; Receptors, Cytoplasmic and Nuclear | 2017 |
Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
Topics: Animals; Biomarkers; Chenodeoxycholic Acid; Humans; Liver; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2016 |
Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system.
Topics: Cell Survival; Cells, Cultured; Chenodeoxycholic Acid; Cholesterol; Hepatocytes; Humans; Non-alcoholic Fatty Liver Disease; Transcriptome | 2017 |
Current management of non-alcoholic fatty liver disease.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet, Healthy; Exercise; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease | 2016 |